Korea Arlico Pharm Co.,Ltd. (KOSDAQ:260660)
South Korea · Delayed Price · Currency is KRW 2,480.00
0.00 (0.00%)
At close: Sep 11, 2026
Korea Arlico Pharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Other Revenue | -0 | -0 | - | - | - | -0 |
| 195,703 | 201,204 | 190,436 | 187,155 | 167,737 | 140,157 | |
Revenue Growth | -3.03% | 5.65% | 1.75% | 11.58% | 19.68% | 12.30% |
Cost of Revenue | 96,030 | 96,974 | 90,708 | 77,038 | 60,871 | 52,672 |
Gross Profit | 99,673 | 104,230 | 99,728 | 110,116 | 106,866 | 87,485 |
Selling, General & Admin | 99,202 | 96,956 | 97,378 | 101,455 | 89,043 | 73,629 |
Research & Development | 6,637 | 5,467 | 4,539 | 4,180 | 6,532 | 8,194 |
Amortization of Goodwill & Intangibles | - | 267.05 | 91.49 | 79.97 | 82.7 | 81.82 |
Other Operating Expenses | 244.74 | 228.18 | 354.96 | 211.67 | 285.4 | 180.17 |
Operating Expenses | 107,689 | 103,241 | 104,887 | 107,044 | 97,002 | 82,691 |
Operating Income | -8,016 | 989.24 | -5,159 | 3,073 | 9,864 | 4,794 |
Interest Expense | -2,156 | -2,156 | -2,105 | -1,587 | -968.39 | -276.95 |
Interest & Investment Income | 230.21 | 230.21 | 338.53 | 435.17 | 518.13 | 167.72 |
Currency Exchange Gain (Loss) | -79.77 | -79.77 | 236.79 | 36.71 | 141.57 | 138.03 |
Other Non Operating Income (Expenses) | 3,663 | -107.66 | -192 | 1,319 | -1,019 | -213.08 |
EBT Excluding Unusual Items | -6,358 | -1,124 | -6,881 | 3,276 | 8,536 | 4,610 |
Gain (Loss) on Sale of Investments | 90.46 | 90.46 | 240.36 | 190.04 | 168.93 | 30.37 |
Gain (Loss) on Sale of Assets | -58.69 | -58.69 | 392.92 | 9.08 | -313.88 | 964.68 |
Other Unusual Items | - | - | 73.26 | - | - | - |
Pretax Income | -6,326 | -1,092 | -6,174 | 3,476 | 8,391 | 5,605 |
Income Tax Expense | -3,475 | -486.6 | -816.11 | 414.67 | 356.96 | 675.18 |
Net Income | -2,851 | -605.35 | -5,358 | 3,061 | 8,034 | 4,930 |
Net Income to Common | -2,851 | -605.35 | -5,358 | 3,061 | 8,034 | 4,930 |
Net Income Growth | - | - | - | -61.90% | 62.98% | -41.12% |
Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 15 |
Shares Outstanding (Diluted) | 15 | 15 | 15 | 29 | 15 | 15 |
Shares Change | -0.33% | 0.03% | -49.01% | 94.89% | 0.18% | -0.06% |
EPS (Basic) | -190.51 | -40.32 | -357.00 | 204.00 | 535.00 | 327.00 |
EPS (Diluted) | -190.51 | -40.32 | -357.00 | 104.00 | 532.00 | 327.00 |
EPS Growth | - | - | - | -80.45% | 62.69% | -41.08% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 15,562 | 6,883 | -12,085 | -16,237 | -14,137 | 3,699 |
Free Cash Flow Per Share | 1039.80 | 458.45 | -805.18 | -551.67 | -936.13 | 245.38 |
Gross Margin | 50.93% | 51.80% | 52.37% | 58.84% | 63.71% | 62.42% |
Operating Margin | -4.10% | 0.49% | -2.71% | 1.64% | 5.88% | 3.42% |
Profit Margin | -1.46% | -0.30% | -2.81% | 1.64% | 4.79% | 3.52% |
Free Cash Flow Margin | 7.95% | 3.42% | -6.35% | -8.68% | -8.43% | 2.64% |
EBITDA | -3,007 | 5,921 | 1,456 | 7,844 | 12,977 | 7,400 |
EBITDA Margin | -1.54% | 2.94% | 0.77% | 4.19% | 7.74% | 5.28% |
D&A For EBITDA | 5,009 | 4,932 | 6,615 | 4,772 | 3,113 | 2,606 |
EBIT | -8,016 | 989.24 | -5,159 | 3,073 | 9,864 | 4,794 |
EBIT Margin | -4.10% | 0.49% | -2.71% | 1.64% | 5.88% | 3.42% |
Effective Tax Rate | - | - | - | 11.93% | 4.25% | 12.05% |
Advertising Expenses | - | 1,030 | 1,096 | 890.82 | 294.4 | 590.9 |